171 related articles for article (PubMed ID: 28667488)
1. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b.
Jadhav AK; Karuppayil SM
In Silico Pharmacol; 2016 Dec; 5(1):4. PubMed ID: 28667488
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase II as a target for repurposed antibiotics in
Jadhav AK; Karuppayil SM
In Silico Pharmacol; 2021; 9(1):24. PubMed ID: 33868894
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, in silico molecular docking analysis, pharmacokinetic properties and evaluation of antibacterial and antioxidant activities of fluoroquinolines.
Fekadu M; Zeleke D; Abdi B; Guttula A; Eswaramoorthy R; Melaku Y
BMC Chem; 2022 Jan; 16(1):1. PubMed ID: 35027086
[TBL] [Abstract][Full Text] [Related]
4. The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting.
Jadhav A; Bansode B; Phule D; Shelar A; Patil R; Gade W; Kharat K; Karuppayil SM
World J Microbiol Biotechnol; 2017 May; 33(5):96. PubMed ID: 28409362
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking studies of curcumin natural derivatives with DNA topoisomerase I and II-DNA complexes.
Kumar A; Bora U
Interdiscip Sci; 2014 Dec; 6(4):285-91. PubMed ID: 25118649
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
7. Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators:
Farouk F; Elmaaty AA; Elkamhawy A; Tawfik HO; Alnajjar R; Abourehab MAS; Saleh MA; Eldehna WM; Al-Karmalawy AA
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2171029. PubMed ID: 36701269
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation.
Perrone CE; Takahashi KC; Williams GM
Toxicol Sci; 2002 Sep; 69(1):16-22. PubMed ID: 12215656
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking Based Analysis to Elucidate the DNA Topoisomerase IIβ as the Potential Target for the Ganoderic Acid; A Natural Therapeutic Agent in Cancer Therapy.
Sharma KK; Singh B; Mujwar S; Bisen PS
Curr Comput Aided Drug Des; 2020; 16(2):176-189. PubMed ID: 31429692
[TBL] [Abstract][Full Text] [Related]
10. 2,4-disubstituted 6-fluoroquinolines as potent antiplasmodial agents: QSAR, homology modeling, molecular docking and ADMET studies.
Shallangwa GA; Mahmud AW; Uzairu A; Ibrahim MT
J Taibah Univ Med Sci; 2024 Apr; 19(2):233-247. PubMed ID: 38179257
[TBL] [Abstract][Full Text] [Related]
11. Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Jamal QMS
Asian Pac J Cancer Prev; 2020 May; 21(5):1349-1355. PubMed ID: 32458643
[TBL] [Abstract][Full Text] [Related]
12. Insight into Mechanism of Action of Anticancer Benzazoles.
Ozturk O; Aki-Yalcin E; Yalcin I; Grifitth R
Curr Top Med Chem; 2020; 20(23):2056-2069. PubMed ID: 32814529
[TBL] [Abstract][Full Text] [Related]
13. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
14. Identification of secondary metabolites from Crescentia cujete as promising antibacterial therapeutics targeting type 2A topoisomerases through molecular dynamics simulation.
Aribisala JO; Abdulsalam RA; Dweba Y; Madonsela K; Sabiu S
Comput Biol Med; 2022 Jun; 145():105432. PubMed ID: 35344868
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
Shapiro AB; Austin CA
Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs.
Shen LL; Baranowski J; Fostel J; Montgomery DA; Lartey PA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2778-84. PubMed ID: 1336349
[TBL] [Abstract][Full Text] [Related]
17. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay.
Yu C; Hu J; Luyten W; Sun D; Jiang T
Chem Biol Drug Des; 2022 Jan; 99(1):92-102. PubMed ID: 34310071
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidine-2,4-dione-linked ciprofloxacin derivatives with broad-spectrum antibacterial, MRSA and topoisomerase inhibitory activities.
Aziz HA; El-Saghier AMM; Badr M; Abuo-Rahma GEA; Shoman ME
Mol Divers; 2022 Jun; 26(3):1743-1759. PubMed ID: 34455532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
